What is Avisi?
Avisi Technologies operates at the intersection of advanced engineering and clinical ophthalmology. The company is dedicated to developing high-impact medical devices, most notably its VisiPlate aqueous shunt and the V-001 sustained intraocular drug-delivery platform. These solutions are engineered to address the significant unmet needs in glaucoma management, particularly for patients undergoing cataract surgery. By integrating sophisticated material science with surgical precision, Avisi has established itself as a critical player in the medical device landscape, supported by a diverse network of academic, governmental, and venture-backed entities. Its market position is bolstered by a commitment to evidence-based medicine and a clear focus on improving patient outcomes through minimally invasive, long-term therapeutic interventions.
How much funding has Avisi raised?
Avisi has raised a total of $10.7M across 1 funding round:
Series A
$10.7M
Series A (2026): $10.7M with participation from MedVenture Partners, OneOneFive, Gemseki, and Golden Seeds
Key Investors in Avisi
MedVenture Partners
A venture capital firm based in Tokyo specializing in medical devices and life sciences, providing risk capital and strategic support for therapeutic innovations.
Gemseki
A division of Shin Nippon Science Co., Ltd. that facilitates the global brokerage of drug discovery seeds and technologies through its specialized marketplace.
Golden Seeds
A New York-based venture capital firm founded in 2005 that focuses on start-up, early-stage, and growth capital investments across various sectors.
What's next for Avisi?
With the successful closure of this major strategic investment, Avisi is poised to enter a pivotal growth phase. The company's strategic roadmap focuses on the advancement of its clinical trials and the optimization of its VisiPlate-S drainage device. Management is expected to prioritize the expansion of its regulatory filings in key international markets, ensuring that its innovative ocular solutions reach clinical settings efficiently. Furthermore, the influx of capital will likely facilitate deeper collaboration with medical device manufacturers and research institutions, potentially accelerating the path toward commercial launch or strategic acquisition. As Avisi continues to refine its drug-delivery platforms, the focus remains on maintaining its trajectory as a leader in ophthalmic innovation, ultimately aiming to provide sustainable, long-term relief for patients worldwide.
See full Avisi company page
